Meeting
2023 ASCO Breakthrough
DNA damage response (DDR) variants and effects on the tumor transcriptome and microenvironment in east Asian (EA) prostate cancers (PCa).
Authors
Boon Hao Hong
National Cancer Centre Singapore, Singapore, Singapore
Boon Hao Hong , Alexander K. Hakansson , Enya Ong , Wen Min Chow , Kae-Jack Tay , Jeffrey K.L. Tuan , Michael L.C. Wang , Lui Shiong Lee , Ravindran Kanesvaran , Yang Liu , Elai Davicioni , Li Yan Khor , Melvin Lee Kiang Chua
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Omics for precision medicine
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 75)
DOI
10.1200/GO.2023.9.Supplement_1.75
Abstract #
75
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal
Poster
2022 ASCO Genitourinary Cancers Symposium
Immune profiling of advanced prostate cancer harboring homologous recombination deficiency.
First Author: Maryam Soleimani
Poster
2020 Genitourinary Cancers Symposium
Genomic profiling of prostate cancer at a diverse academic center.
First Author: Robert Lopez
Poster
2024 ASCO Breakthrough
A pan-tumor description of the genomic, transcriptomic, and immunological landscape of sodium-glucose cotransporter-2 (SGLT2) and association with clinical outcomes.
First Author: Heng Tan